Their research shows that viruses designed to kill cancer cells – oncolytic viruses – might be more effective against aggressive brain tumors if they also carry a gene for a protein that inhibits blood-vessel growth.
The protein, called vasculostatin, is normally produced in the brain. In this study, an oncolytic virus containing the gene for this protein in some cases eliminated human glioblastoma tumors growing in animals and significantly slowed tumor recurrence in others. Glioblastomas, which characteristically have a high number of blood vessels, are the most common and devastating form of human brain cancer. People diagnosed with these tumors survive less than 15 months on average after diagnosis.
"This is the first study to report the effects of vasculostatin delivery into established tumors, and it supports further development of this novel virus as a possible cancer treatment," says study leader Balveen Kaur, associate professor of neurological surgery and a researcher with the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. "Our findings suggest that this oncolytic virus is a safe and promising strategy to pursue for the treatment of human brain tumors.
"This study shows the potential of combining an oncolytic virus with a natural blood-vessel growth inhibitor such as vasculostatin. Future studies will reveal the potential for safety and efficacy when used in combination with chemotherapy and radiation therapy," she says.
The findings were recently published online in the journal Molecular Therapy.
Jayson Hardcastle, a graduate student in Dr. Kaur's laboratory, injected the cancer-killing virus, called RAMBO (for Rapid Antiangiogenesis Mediated By Oncolytic virus), directly into human glioblastoma tumors growing either under the skin or in the brains of mice.
Of six animals with tumors under the skin, those treated with RAMBO survived an average of 54 days. In addition, three of the RAMBO mice were tumor-free at the end of the experiment. Control animals treated with a similar virus that lacked the vasculostatin gene, on the other hand, survived an average of 26 days and none were tumor-free.
Of the animals with a human glioblastoma in the brain, five were treated with RAMBO and lived an average of 54 days. One animal remained tumor-free for more than 120 days. Control animals, by comparison, lived an average of 26 days with no long-term survivors.
In another experiment, the investigators followed the course of tumor changes in animals with tumors in the brain. After an initial period of tumor shrinkage, the remaining cancer cells began regrowing around day 13 in animals given the virus that lacked the blood-vessel inhibitor. In animals treated with RAMBO, tumor regrowth didn't begin until about day 39.
"With additional research, this virus could lead to a new therapeutic strategy for combating cancer," Kaur says.
Darrell E. Ward | EurekAlert!
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences